Medical Advocates

Atazanavir (Reyataz)
 
Main Page

New and Noteworthy
Drug Alerts
Product Information
Database of ARV Drug Interactions
Guidelines
Journal Papers, Abstracts, and Commentaries
Conference Reports, Abstracts, and Posters
Treatment Guidelines/Recommendations
Pediatric Data
Perinatal Data
Protease Inhibitors: General Data

 

 

ARV Drugs Main Page New/Newsworthy Home Page      

This web page is best viewed by using INTERNET EXPLORER
Last updated:  July 20, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy
     

July 2008
 
June 2008
 

Drug Alerts
       

Atazanavir
 
 
PACKAGE INSERT PDF UPDATE
The Reyataz (atazanavir) Capsule label has been updated to include the
dosing recommendations for pediatric patients 6 to 18 years of age.

USFDA  
March 26, 2008
News Release
 
PACKAGE INSERT UPDATE
Atazanavir Package Insert Revised
US FDA
January 16, 2007
News Release
 
FDA Approves a 300 mg Capsule Form of Reyataz
FDA  
October 14, 2006
News Release
 
BMS DRUG ALERT
REYATAZ (atazanavir sulfate) With or Without Norvir® (ritonavir) and Proton Pump Inhibitors
Should Not Be Coadministered: Important New Pharmacokinetic Data

Sally Hodder MD
November 2004
Letter

FDA Safety and Adverse Warning Alert
MedWatch March 2004


Atazanavir/Tenofovir
 
BMS DRUG ALERT
Important New Pharmacokinetic Data for REYATAZ (atazanavir sulfate) in combination with
Viread (tenofovir disoproxil fumarate)
S Hodder,
August 08, 2003

PDF Letter


ARV Drugs Main Page New/Newsworthy Home Page      

Atazanavir Main Page